Cipher Mining Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Cipher Mining Inc trades at $19.75 (market cap $8.13B), while Regeneron Pharmaceuticals Inc trades at $655.64 (market cap $68.79B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.5× Cipher Mining Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Cipher Mining Inc pays none. Which is the better fit depends on your goals.
| CIFR | REGN | |
|---|---|---|
Market Cap | $8.13B | $68.79B |
Sector | Basic Materials | Health |
52-Week High | $29.18 | $812.27 |
52-Week Low | $4.72 | $542.52 |
Enterprise Value | $12.16B | $62.74B |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
CIFR trades at $20.085, down 9.16% over 24 hours, reflecting bearish technical signals despite unanimous analyst buy ratings. The company is transitioning from Bitcoin mining to AI data center operations, evidenced by a $11.4B contracted revenue backlog but faces significant financial strain with a -427.79% net income margin and negative cash flow from operations. Recent news highlights volatility driven by AI infrastructure developments and capital raises.
The outlook hinges on successful execution of its AI data center pivot, offering substantial upside to the $32.81 consensus price target, but high valuation multiples and persistent losses pose near-term risks. Investors must weigh transformative growth potential against cash burn and execution challenges in a competitive sector.
Regeneron (REGN) trades at $663.09, down slightly by 0.22% on the day, with a bullish technical signal supported by moving averages. The company maintains strong profitability, with a net income margin of 29.65% and consistent earnings beats in recent quarters. Recent positive news includes FDA and EMA acceptance of its cemdisiran application for gMG and selection for an FDA pilot program to accelerate manufacturing reviews, highlighting operational momentum.
The outlook remains positive given analyst consensus with a $764.50 price target and no sell ratings, though risks include regulatory hurdles and competitive pressures in biotech. Earnings growth and pipeline advancements are key catalysts, but investors should weigh high RSI levels suggesting potential near-term overbought conditions against strong fundamental performance.
Trailing returns across standard periods
Latest headlines on both assets
Cipher Mining is an industrial-scale technology company focused on Bitcoin mining infrastructure. It develops and operates data centers in the US designed to strengthen the Bitcoin network and support decentralized finance.
Read more on CIFR →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →